ATE550351T1 - Vegf-d-mutanten und ihre verwendung - Google Patents

Vegf-d-mutanten und ihre verwendung

Info

Publication number
ATE550351T1
ATE550351T1 AT08762227T AT08762227T ATE550351T1 AT E550351 T1 ATE550351 T1 AT E550351T1 AT 08762227 T AT08762227 T AT 08762227T AT 08762227 T AT08762227 T AT 08762227T AT E550351 T1 ATE550351 T1 AT E550351T1
Authority
AT
Austria
Prior art keywords
vegf
mutants
angiogenesis
promotion
therapy
Prior art date
Application number
AT08762227T
Other languages
English (en)
Inventor
Pyry Toivanen
Kari Airenne
Seppo Ylae-Herttuala
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Application granted granted Critical
Publication of ATE550351T1 publication Critical patent/ATE550351T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08762227T 2007-05-31 2008-06-02 Vegf-d-mutanten und ihre verwendung ATE550351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0710457.3A GB0710457D0 (en) 2007-05-31 2007-05-31 Vegf Mutants
PCT/GB2008/001873 WO2008146023A1 (en) 2007-05-31 2008-06-02 Vegf-d mutants and their use

Publications (1)

Publication Number Publication Date
ATE550351T1 true ATE550351T1 (de) 2012-04-15

Family

ID=38289657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08762227T ATE550351T1 (de) 2007-05-31 2008-06-02 Vegf-d-mutanten und ihre verwendung

Country Status (13)

Country Link
US (1) US8188039B2 (de)
EP (1) EP2162463B1 (de)
JP (1) JP2010527627A (de)
KR (1) KR101522043B1 (de)
CN (1) CN101730710A (de)
AT (1) ATE550351T1 (de)
AU (1) AU2008256550B2 (de)
BR (1) BRPI0812026A2 (de)
CA (1) CA2688543C (de)
EA (1) EA200971092A1 (de)
GB (1) GB0710457D0 (de)
MX (1) MX2009012599A (de)
WO (1) WO2008146023A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010090523A1 (en) * 2009-02-06 2010-08-12 Pepscan Systems B.V. Truncated cystine-knot proteins
CN102336811B (zh) * 2010-07-26 2016-03-16 上海市第一人民医院 一类新的抑制新生血管的小肽及其应用
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof

Also Published As

Publication number Publication date
CA2688543A1 (en) 2008-12-04
WO2008146023A1 (en) 2008-12-04
KR101522043B1 (ko) 2015-05-20
GB0710457D0 (en) 2007-07-11
AU2008256550A1 (en) 2008-12-04
JP2010527627A (ja) 2010-08-19
EP2162463A1 (de) 2010-03-17
EP2162463B1 (de) 2012-03-21
CA2688543C (en) 2017-08-22
EA200971092A1 (ru) 2010-06-30
MX2009012599A (es) 2009-12-11
US20110144013A1 (en) 2011-06-16
CN101730710A (zh) 2010-06-09
BRPI0812026A2 (pt) 2015-09-29
AU2008256550B2 (en) 2012-02-09
KR20100040805A (ko) 2010-04-21
US8188039B2 (en) 2012-05-29

Similar Documents

Publication Publication Date Title
ATE554785T1 (de) Modifizierte fgf-21 polypeptide und ihre verwendung
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
UA94221C2 (en) Lipocalin protein
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
EA201301350A1 (ru) Модифицированные полипептиды фактора vii и их применение
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
ATE499088T1 (de) Glp-1-fc fusionsprotein-formulierung
CY1115535T1 (el) Αναστολεις δραστικοτητας ακτ
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
GT201200189A (es) Antagonistas de pcsk9
DE602004024037D1 (de) Substituierte heterozyklen
DE50310516D1 (de) Fredericamycin-derivate
CY1114952T1 (el) Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
WO2008093165A3 (en) The use of pgil ohgosaccharyltransferase for o-glycosylating proteins
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ATE484749T1 (de) Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung
DK2118136T3 (da) Konsensuspeptid
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
DE602006008834D1 (de) Binäre hyaluronsäure-gemische und ihre therapeutische verwendung
EA201070195A1 (ru) ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
EA200971092A1 (ru) Vegf-d мутанты и их применение
WO2008070552A3 (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
DE602005025231D1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen